Olmesartan medoxomil, a newly developed angiotensin ii type 1 receptor antagonist, protects against renal damage in advanced glycation end product (age)-injected rats

Drugs under Experimental and Clinical Research

Volumn 31, Issue 2, 2005, Pages 45-51

  Yamagishi, Sho Ichi ^a   Takeuchi, M ^b   Inoue, H ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b HOKURIKU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; N ACETYL BETA GLUCOSAMINIDASE; OLMESARTAN; ADVANCED GLYCATION END PRODUCT; ANGIOTENSIN 2 RECEPTOR; IMIDAZOLE DERIVATIVE; N ACETYLGLUCOSAMINE; TETRAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; ENZYME ACTIVITY; GLOMERULOSCLEROSIS; GLYCATION; KIDNEY INJURY; MALE; NONHUMAN; PROTEINURIA; RAT; SYSTOLIC BLOOD PRESSURE; ANIMAL; BODY WEIGHT; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; DRUG EFFECT; FOCAL GLOMERULOSCLEROSIS; KIDNEY DISEASE; PATHOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT; TISSUE FIXATION; URINE;

ACETYLGLUCOSAMINE; ANIMALS; BODY WEIGHT; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; GLYCOSYLATION END PRODUCTS, ADVANCED; IMIDAZOLES; KIDNEY DISEASES; MALE; PROTEINURIA; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR CROSS-TALK; RECEPTOR, ANGIOTENSIN, TYPE 2; RENIN-ANGIOTENSIN SYSTEM; TETRAZOLES; TISSUE FIXATION;

EID: 23244447260     PISSN: 03786501     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Friedman E.A. Diabetic renal disease. In: Lifkin H., Porte D. (Eds.). "Ellenberg and Rifkin's Diabetes Mellitus, Theory and Practice." Elsevier, New York, 1990, p. 684.
2. Yamagishi S., Takeuchi M., Makita Z. Advanced glycation end products and the pathogenesis of diabetic nephropathy. Contrib. Nephrol., 134, 30, 2001.
3. Yamagishi S., Inagaki Y., Amano S., et al. Advanced glycation end product-induced apoptosis and overexpression of vascular endothelial growth factor and monocyte chemoattractant protein-1 in human-cultured mesangial cells. J. Biol. Chem., 277, 20309, 2002.
4. Yamagishi S., Inagaki Y,, Okamoto T., Amano S., Koga K., Takeuchi M. Advanced glycation end products inhibit de novo protein synthesis and induce TGF-β overexpression in proximal tubular cells. Kidney Int., 63, 464, 2003.
5. Brownlee M. Advanced protein glycosylation in diabetes and aging. Ann. Rev. Med., 46, 223, 1995.
6. Bierhaus A., Hofmann M.A., Ziegler R., Nawroth P.P. AGES and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept. Cardiovasc. Res., 37, 586, 1998.
7. Schmidt A.M, Stern D. Atherosclerosis and diabetes: The RAGE connection. Curr. Atheroscler. Rep., 2, 430, 2002.
8. Stitt A.W., Li Y.M., Gardiner T.A., et al. Advanced glycation end products (AGEs) co-locarize with AGE receptors in the retinal vasculature of diabetic and AGE-infused rats. Am. J. Pathol., 150, 523, 1997.
9. Yamagishi S., Takeuchi M., Inagaki Y., Nakamura K., Imaizumi T. Role of advanced glycation end products (AGEs) and their receptor (RAGE) in the pathogenesis of diabetic microangiopathy. Int. J. Clin. Pharm. Res., 23, 129, 2003.
10. Yamagishi S., Hsu C.C., Taniguchi M., et al. Receptor-mediated toxicity to pericytes of advanced glycosylation end products: A possible mechanism of pericyte loss in diabetic microangiopathy. Biochem. Biophys. Res. Commun., 213, 68, 1995.
11. Yamagishi S., Amano S., Inagaki Y., et al. Advanced glycation end products-induced apoptosis and overexpression of vascular endothelial growth factor in bovine retinal pericytes. Biochem. Biophys. Res. Commun., 290, 973, 2002.
12. Yamagishi S., Inagaki Y., Amano S., et al. Pigment epithelium-derived factor protects cultured retinal pericytes from advanced glycation end product-induced injury through its antioxidative properties. Biochem. Biophys. Res. Commun., 296, 877, 2002.
13. Yamagishi S., Okamoto T., Amano S., et al. Palmitate-induced apoptosis of microvascular endothelial cells and pericytes. Mol. Med., 8, 178, 2002.
14. Tanaka N., Yonekura H., Yamagishi S., et al. The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factor-alpha through nuclear factor-kappa B, and by 17beta-estradiol through Sp-1 in human vascular endothelial cells. J. Biol. Chem., 275, 25781, 2000.
15. 2 analogue, protects against advanced glycation end products-induced injury in cultured retinal pericytes. Mol. Med., 8, 547, 2002.
16. Yamagishi S., Yamamoto Y., Harada S., Hsu C.C., Yamamoto H. Advanced glycosylation end products stimulate the growth but inhibit the prostacyclin-producing ability of endothelial cells through interactions with their receptors. FEBS Lett., 384, 103, 1996.
17. Yamagishi, S., Yonekura, H., Yamamoto, Y., et al. Advanced glycation end products-driven angiogenesis in vitro. Induction of the growth and tube formation of human microvascular endothelial cells through autocrine vascular endothelial growth factor. J. Biol. Chem., 272, 8723, 1997.
18. Yamagishi S., Fujimori H., Yonekura H., Yamamoto Y., Yamamoto H. Advanced glycation endproducts inhibit prostacyclin production and induce plasminogen activator inhibitor-1 in human microvascular endothelial cells. Diabetologia, 41, 1435, 1998.
19. Okamoto T., Yamagishi S., Inagaki Y., et al. Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin. FASEB J., 16, 1928, 2002.
20. Inagaki Y., Yamagishi S., Okamoto T., Takeuchi M., Amano S. Pigment epithelium-derived factor prevents advanced glycation end products-induced monocyte chemoattractant protein-1 production in microvascular endothelial cells by suppressing intracellular reactive oxygen species generation. Diabetologia, 46, 284, 2003.
21. Forbes J.M., Cooper M.E., Oldfield M.D., Thomas M.C. Role of advanced glycation endproducts in diabetic nephropathy. J. Am. Soc. Nephrol., 14, S254, 2003.
22. Metz T.O., Alderson N.L., Thorpe S.R., Baynes J.W. Pyridoxamine, an inhibitor of advanced glycation and lipoxidation reactions: A novel therapy for treatment of diabetic complications. Arch. Biochem. Biophys., 419, 41, 2003.
23. Carey R.M., Siragy H.M. The intrarenal renin-angiotensin system and diabetic nephropathy. Trends Endocrinol. Metab., 14, 274, 2003.
24. Cooper M., Boner G. Dual blockade of the renin-angiotensin system in diabetic nephropathy. Diabet. Med., 21, 15, 2004.
25. Burns K.D. Angiotensin II and its receptors in the diabetic kidney. Am. J. Kidney Dis., 36, 449, 2000.
26. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. BMJ., 317, 703, 1998.
27. The EUCLID Study Group. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet, 349, 1787, 1997.
28. Brenner B.M., Cooper M.E., de Zeeuw D., et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med., 345, 861, 2001.
29. Lewis E.J., Hunsicker L.G., Clarke W.R., et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Engl. J. Med., 345, 851, 2001.
30. Nussberger J., Koike H. Antagonizing the angiotensin II subtype 1 receptor: A focus on olmesartan medoxomil. Clin. Ther., 26, A12, 2004.
31. Koga K., Yamagishi S., Takeuchi M., et al. CS-866, a new angiotensin II type 1 receptor antagonist, ameriorates glomerular anionic site loss and prevents progression of diabetic nephropathy in Otsuka Long-Evans Tokushima Fatty rats. Mol. Med., 8, 591, 2002.
32. Yamagishi S., Koga K., Inagaki Y., Amano S., Okamoto T., Takeuchi M. Dilazep hydrochloride, an antiplatelet drug, prevents progression of diabetic nephropathy in Otsuka Long-Evans Tokushima Fatty rats. Drugs Exptl. Clin. Res., 28, 221, 2002.
33. Raij L., Azar S., Keane W. Mesangial immune injury, hypertension, and progressive glomerular damage in Dahl rats. Kidney Int., 26, 137, 1984.
34. Saito T., Sumithraum E., Glasgow E.F., Atkins R.C. The enhancement of aminonucleoside nephrosis by the co-administration of proamine. Kidney Int., 32, 691, 1987.
35. Nakamura T., Obata J., Kimura H., et al. Blocking angiotensin II ameliorates proteinuria and glomerular lesions in progressive mesangioproliferative glomerulonephritis. Kidney Int., 55, 877, 1999.
36. Bucala R., Tracey K.J., Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J. Clin. Invest., 87, 432, 1991.
37. Ceriello A. Hyperglycaemia: The bridge between non-enzymatic glycation and oxidative stress in the pathogenesis of diabetic complications. Diabetes Nutr. Metab., 12, 42, 1999.
38. Chakravarthy U., Hayes R.G., Stitt A.W., McAuley E., Archer D.B. Constitutive nitric oxide synthase expression in retinal vascular endothelial cells is suppressed by high glucose and advanced glycation end products. Diabetes, 47, 945, 1998.
39. Xu B., Chibber R., Ruggiero D., et al. Impairment of vascular endothelial nitric oxide synthase activity by advanced glycation end products. FASEB J., 17, 1289, 2003.
40. Mizutani K., Ikeda K., Tsuda K., Yamori Y. Inhibitor for advanced glycation end products formation attenuates hypertension and oxidative damage in genetic hypertensive rats. J. Hypertens., 20, 1607, 2002.
41. Taft J., Nolan C.J., Yeung S.P., et al. Clinical and histological correlations of decline in renal function in diabetic patients with proteinuria. Diabetes, 43, 1046, 1994.
42. Ziyadeh F.N., Goldfarb S. The renal tubulointerstitium in diabetes mellitus. Kidney Int., 39, 464, 1991.
43. Gilbert R.E., Cooper M.E. The tubulointerstitium in progressive diabetic kidney disease: More than an aftermath of glomerular injury? Kidney Int., 56, 1627, 1999.
44. Shaw S.S., Schmidt A.M., Banes A.K., et al. S100B-RAGE-mediated augmentation of angiotensin II-induced activation of JAK2 in vascular smooth muscle cells is dependent on PLD2. Diabetes, 52, 2381, 2003.
45. Fukami K., Ueda S., Yamagishi S., et al. AGEs activate mesangial TGF-β signaling via an angiotensin II-type 1 receptor interaction. Kidney Int., 66, 2137, 2004.
46. Stumpe K.O. Olmesartan compared with other angiotensin II receptor antagonists: Head-to-head trials. Clin. Ther., 26, A33, 2004.